Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Editorial Article
Overview
abstract
The combination of chemotherapy and immune therapies still promises to synergize for prolonged tumor control. However, the quest for optimal combinations tailored for tumor histology remains ongoing. A recent study provides evidence on the feasibility of the trabectedin/durvalumab combination and reports on interesting preliminary efficacy. See related article by Toulmonde et al., p. 1765.
